由 Brendon Nafziger
, DOTmed News Associate Editor | August 30, 2013
From the September 2013 issue of HealthCare Business News magazine
Still, the clinical evidence will have to come in before clinicians will jump on board.
“That’s generally a treatment modality that hasn’t been used in clinical trials as yet. It’ll be interesting to see what the side effect profile looks like with those treatments,” Sloan-Kettering’s Dr. Coleman says. He also says modalities like HistoSonics’ are generally being researched for the treatment of benign disease, possibly because the jury’s out on whether they can be used for cancer, as they might not have the full “tissue-destructive” effects of HIFU.
“The problem that we struggle with in the treatment of any cancer is you’ve got to kill every single cancer cell or make sure those cancer cells will die after treatment,” Dr. Coleman explains, because even if a “small number survive they can proliferate and grow.”
Click here to read part one
Back to HCB News